Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Business revenue was recognized from milestone income received from Toray Medical for the development of AI-equipped hemodialysis medical equipment, while ¥90,511 thousand in business expenses, including ¥41,806 thousand in research and development expenses, was recognized.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥10 million (YoY 0.0%) |
| Operating profit | ¥-82 million |
| Ordinary income | ¥-81 million |
| Profit attributable to owners of the parent | ¥-82 million |
| Net income per share | △¥5.95 |
| Equity ratio | End of the current fiscal period 98 / End of previous period 94.5 |
| Total assets | ¥3,293 million |
| Net assets | ¥3,240 million |
| Cash and cash equivalents at end of period | ¥3,204,574 thousand |
| Full-year earnings forecast | Net Sales ¥43 million (YoY -36.4%) / Operating profit ¥-585 million / Ordinary income ¥-547 million / Net income ¥-548 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥18 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | On 7 August 2026, the reduction of the capital reserve by ¥1,136,328,774, its transfer to other capital surplus, and the transfer of the same amount to retained earnings brought forward for application to offset the deficit became effective. This had no impact on net assets or financial results. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 13,776,900 |
| Treasury Shares at Period-End | 10 |
| Factors Behind Changes in Business Performance | Business revenue was recognized from milestone income received from Toray Medical for the development of AI-equipped hemodialysis medical equipment, while ¥90,511 thousand in business expenses, including ¥41,806 thousand in research and development expenses, was recognized. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue was generated from milestone income received from Toray Medical for the development of AI-equipped hemodialysis medical equipment. The operating loss resulted from the recognition of ¥90,511 thousand in business expenses, including ¥41,806 thousand in research and development expenses.